IP Library Patent Application 16533676
Patent Application
App. No. 16/533,676

MULTI-MODAL APPROACH TO PREDICTING IMMUNE INFILTRATION BASED ON INTEGRATED RNA EXPRESSION AND IMAGING FEATURES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/533,676
Abstract

Multi-modal approaches to predict tumor immune infiltration are based on integrating gene expression data and imaging features in a neural network-based framework. This framework is configured to estimate percent composition, and thus immune infiltration score, of a patient tumor biopsy sample. Multi-modal approaches may also be used to predict cell composition beyond immune cells via integrated multi-layer neural network frameworks.

Claims (29)

1 . A computing device configured to generate an immune infiltration prediction score, the computing device comprising one or more processors configured to:

obtain gene expression data from one or more gene expression datasets with the gene expression data corresponding to one or more tissue samples;

obtain a set of stained histopathology images from one or more image sources and corresponding to the one or more tissue samples;

determine imaging features from the set of stained histopathology images, the imaging features comprising texture and/or intensity features;

in a neural network framework, transform the gene expression data using a gene expression neural network layer(s) and transform the imaging features using an imaging feature neural network layer(s);

in the neural network framework, integrate an output of the gene expression neural network layer(s) and the imaging feature neural network layer(s) to produce an integrated neural network output; and

apply a prediction function to the integrated neural network output and output an immune infiltration score for the one or more tissue samples.

2 .- 3 . (canceled)

4 . The computing device of claim 1 , wherein the gene expression data is RNA sequencing data.

5 . The computing device of claim 1 , wherein the neural network framework comprises two neural network layers.

6 . The computing device of claim 1 , wherein the imaging features comprise mean, standard deviation, skewness, and/or sum of image gray level, image red, green, blue layers, stain layers, optical density, hue, and/or saturation.

7 . The computing device of claim 1 , wherein the imaging features comprise Zernike moments, threshold adjacency analysis values, local binary patterns, gray scale co-occurrence matrix, and/or difference of Gaussian statistical measures.

8 . The computing device of claim 1 , wherein the prediction function is Softmax function.

9 . The computing device of claim 1 , wherein immune infiltration score comprises a predicted percentage of natural killer (NK) cells, (MAC) macrophage cells, CD4 T cells, CD8 T cells, and B cells, regulatory T cells, Dendritic cells, monocytes, Mast cells, Eosinophils, and Neutrophils.

10 . The computing device of claim 1 , wherein immune infiltration score comprises a predicted percentage of others cells, including stromal cells, vasculature cells, fat cells, tumor cells, stem cells, neural cells, progenitor cells, innate lymphoid cells, microglial cells, leukocytes, naïve B cells, memory B cells, Plasma cells, CD8 T cells, naïve CD4 T cells, memory CD4 T cells, follicular helper T cells, regulatory T cells, gamma delta T cells, Th17 T cells, unstimulated NK cells, stimulated NK cells, Macrophages MO, Macrophages M1, Macrophages M2, unstimulated Dendritic cells, stimulated Dendritic cells, unstimulated Mast cells, stimulated Mast cells.

11 . The computing device of claim 1 , wherein the contextual data is a total immune fraction or total tumor fraction.

12 . A computer-implemented method to generate an immune infiltration prediction score, the method comprising:

obtaining a gene expression data from one or more gene expression datasets with the gene expression data corresponding to one or more tissue samples;

obtaining a set of stained histopathology images from one or more image sources and corresponding to the one or more tissue samples;

determining imaging features from the set of stained histopathology images, the imaging features comprising texture and/or intensity features;

in a neural network framework, transforming the gene expression data using a gene expression neural network layer(s) and transforming the imaging features using an imaging feature neural network layer(s);

in the neural network framework, integrating an output of the gene expression neural network layer(s) and the imaging feature neural network layer(s) to produce an integrated neural network output; and

applying a prediction function to the integrated neural network output and outputting an immune infiltration score for the one or more tissue samples.

13 .- 14 . (canceled)

15 . The computer-implemented method of claim 12 , further comprising obtaining the gene expression data from an RNA sequencing data source communicatively coupled to a communication network, the gene expression data comprising RNA sequencing data.

16 . The computer-implemented method of claim 15 , wherein the gene expression data is raw gene expression data.

17 . The computer-implemented method of claim 15 , wherein the gene expression data is RNA sequencing data for selected genes.

18 . The computer-implemented method of claim 12 , wherein the gene expression data is RNA sequencing data, the method further comprising performing a gene selection on the RNA sequencing data.

19 . The computer-implemented method of claim 12 , further comprising: tilting each of the set of stained histopathology images to generate a plurality of patches; and determining the imaging features from the plurality of patches.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 13, 2026
From: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
To: TEMPUS AI, INC. (F/K/A TEMPUS LABS, INC.)
Reel/Frame 075608/0784 →
CHANGE OF NAME Recorded Feb 9, 2024
From: TEMPUS LABS, INC.
To: TEMPUS AI, INC.
Reel/Frame 066544/0110 →
SECURITY INTEREST Recorded Sep 22, 2022
From: TEMPUS LABS, INC.
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 061506/0316 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2020
From: LAU, DENISE; KHAN, ALY AZEEM
To: TEMPUS LABS, INC.
Reel/Frame 051567/0250 →